AUA: Atenolol linked to drop in low-, intermediate-risk prostate cancer

(HealthDay)—Atenolol is associated with a reduction in incident intermediate- and low-risk prostate cancer (PCa), according to a study presented at the annual meeting of the American Urological Association, held from May 3 to 6 in Chicago.

* This article was originally published here